Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trialNat. Med. 2022 Oct 01;28(10)2083-2091, WT Garvey, RL Batterham, M Bhatta, S Buscemi, LN Christensen, JP Frias, E Jódar, K Kandler, G Rigas, TA Wadden, S Wharton
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.